J. Goldman & Co’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

J. Goldman & Co’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,000	Closed	-$1.14M	–	538
2022 Q4	$1.14M	Buy	+10,000	New	+$831K	0.06%	217
2022 Q3	–	Sell	-54,000	Closed	-$4.31M	–	539
2022 Q2	$4.31M	Buy	+54,000	New	+$5.11M	0.21%	119
2017 Q2	–	Sell	-56,000	Closed	-$828K	–	454
2017 Q1	$828K	Sell	56,000 -126,000	-69%	-$2.04M	0.04%	262
2016 Q4	$2.94M	Sell	182,000 -104,000	-36%	-$1.89M	0.2%	144
2016 Q3	$5.18M	Buy	+286,000	New	+$5.59M	0.29%	99
2014 Q1	–	Sell	-175,000	Closed	-$1.33M	–	320
2013 Q4	$1.33M	Sell	175,000 -57,500	-25%	-$310K	0.17%	140
2013 Q3	$779K	Buy	+232,500	New	+$613K	0.07%	214

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

J. Goldman & Co's HZNP Position: Q3 2022 in Review

J. Goldman & Co sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 37,761 shares — an estimated $3.01M sold.

J. Goldman & Co first reported a position in HZNP in Q3 2013 and held it in 8 quarters. The position peaked at $5.09M in Q4 2013. 530 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

J. Goldman & Co reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
J. Goldman & Co sold 37,761 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $3.01M.
J. Goldman & Co first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2013 and held it in 8 quarters.
J. Goldman & Co's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $5.09M in Q4 2013.
530 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on J. Goldman & Co's 13F filing for Q3 2022, filed 14 Nov 2022.